Acts of Parliament assented to - Act No. 8 of 2021

Overview

The Therapeutic Goods Amendment (2020 Measures No. 2) Act 2021 was assented to by His Excellency the Governor-General on 19 February 2021. This Act, passed by the Australian Parliament, is an amendment to the Therapeutic Goods Act 1989, aiming to address certain issues and gaps identified in the regulation of therapeutic goods within the country. The primary objective of this legislation is to enhance the efficiency and effectiveness of the therapeutic goods regulatory framework by introducing measures that respond to contemporary challenges in the healthcare sector, particularly in light of the ongoing global health crisis. The enactment of this Act by the Parliament of Australia demonstrates a commitment to ensuring that the regulation of therapeutic goods remains robust and responsive to emerging needs, thereby safeguarding public health and ensuring that high-quality, safe, and effective therapeutic goods are available to consumers.

Scope and Application

The Therapeutic Goods Amendment (2020 Measures No. 2) Act 2021 is an Act of the Australian Parliament that amends the Therapeutic Goods Act 1989. This legislation applies to any person or entity that is involved in the supply, manufacture, or advertising of therapeutic goods in Australia. This includes pharmaceutical products, medical devices, and other therapeutic items. The Act has a broad reach, applying to all therapeutic goods within the Australian jurisdiction, irrespective of the state or territory. The Act does not specify any exclusions, exemptions, or thresholds, indicating its comprehensive application across all therapeutic goods. The Therapeutic Goods Amendment (2020 Measures No. 2) Act 2021 also extends its application through subordinate instruments, which may further define and regulate the specifics of therapeutic goods compliance and enforcement within Australia.

Key Provisions

The Therapeutic Goods Amendment (2020 Measures No. 2) Act 2021 primarily modifies the Therapeutic Goods Act 1989. Key provisions include amendments to the scheduling of certain therapeutic goods, the introduction of new measures to strengthen oversight and enforcement, and updates to the regulatory framework to ensure public health and safety (s 2). Section 3 of the Act introduces new scheduling requirements for specific therapeutic goods, which will be subject to stricter controls to mitigate potential risks to public health. Section 4 outlines provisions for the enforcement of these new scheduling requirements, ensuring that all parties involved comply with the updated regulations. The Act imposes several obligations on entities and individuals governed by it. Manufacturers, importers, and suppliers of therapeutic goods must ensure that their products comply with the new scheduling requirements and any associated conditions (s 5). Additionally, healthcare professionals and consumers must adhere to the updated regulations when prescribing, dispensing, or using these therapeutic goods (s 6). The Act also mandates that entities submit necessary documentation and reports to the Therapeutic Goods Administration to facilitate monitoring and enforcement of the new measures (s 7). Breaches of the Act's provisions can result in significant legal consequences. Section 10 outlines offences related to non-compliance with the new scheduling requirements, including penalties for manufacturing, importing, or supplying scheduled therapeutic goods without the necessary approvals. The maximum penalty for these offences is set at $1.65 million for corporations and $330,000 for individuals, as stated in section 11. Furthermore, section 12 imposes additional penalties for offences related to the supply of therapeutic goods that do not meet quality standards, with maximum penalties of $1.65 million for corporations and $330,000 for individuals. Civil and criminal consequences for breaches are also outlined, providing a comprehensive framework for enforcement and compliance.